Dolutegravir, abacavir and lamivudine as HIV therapy

By Fernandez-Montero Jose Vicente   Barreiro Pablo   Labarga Pablo   De Mendoza Carmen   Soriano Vicente  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 1051-1057

Informa Healthcare

Access to resources Recommend Favorite

Novel Second Generation HIV Integrase Inhibitor-DOLUTEGRAVIR: An Emerging Weapon Against HIV

By  

Letters in Drug Design & Discovery, Vol. 14, Iss. 3, 2017-01 ,pp. : 354-371

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Single‐Dose Dolutegravir in HIV‐Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

By  

Clinical Pharmacology In Drug Development, Vol. 2, Iss. 4, 2013-10 ,pp. : 342-348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of HIV infection with raltegravir

By Chirch Lisa M   Morrison Sidonie   Steigbigel Roy T  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 7, 2009-05 ,pp. : 1203-1211

Informa Healthcare

Access to resources Recommend Favorite

Etravirine for the treatment of HIV/AIDS

By Schrijvers Rik  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1087-1096

Informa Healthcare

Access to resources Recommend Favorite